The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk

Recruiting now · Not applicable

Conditions studied: Lung Cancer

In brief

This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.

Key facts

Study ID

NCT07458425

Run by

University of Illinois at Chicago

People needed

400

Starts

2026-03-11

Expected to finish

2029-01-01

Last updated by the study team

2026-04-06

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must be 50-80 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
• Participants must be eligible for LDCT screening as defined by the USPSTF
• USPSTF-eligible patients at UI Health and Mile Square FQHC, including primary care and substance use disorder clinics.
• Adults who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
• Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. Consent provided by a legally authorized representative is not permitted in this protocol.
• Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
• Ability of the subject to understand and comply with study procedures for the entire length of the study.

You may not qualify if…

• Adults who have more than 20 pack-years history but who have not smoked for 15 years or more prior to informed consent (i.e., quit smoking for 15 or more years).
• Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
• Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 5 years prior to the expected enrollment date, or diagnosed greater than 5 years prior to the expected enrollment date and never treated. Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded.
• Prior/Concurrent Concomitant Therapy (Medications/Treatments): Definitive treatment for invasive solid tumor or hematologic malignancy within the 5 years prior to the expected enrollment date. Adjuvant hormone therapy for cancer (e.g., for breast or prostate cancer) is not an exclusion criterion.
• Individuals who will not be able to comply with the protocol procedures.
• Individuals who are not currently registered patients at UIH
• Current pregnancy (by self-report of pregnancy status)

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.